PharmaCyte Biotech, Inc.
$0.76
▲
0.1%
2026-04-21 08:53:01
pharmacyte.com
NCM: PMCB
Explore PharmaCyte Biotech, Inc. stock price, valuation, financial statements, dividend history, analyst estimates, and long-term business fundamentals on StockSifting.
Market Cap
$7.82 M
Current Price
$0.76
52W High / Low
$1.51 / $0.63
Stock P/E
—
Book Value
$3.59
Dividend Yield
—
ROCE
-8.38%
ROE
-8.24%
Face Value
—
EPS
$-0.89
Exp Qtr EPS
—
Sector
Healthcare
Industry
Biotechnology
Employees
2
Beta
0.41
Debt / Equity
—
Current Ratio
12.33
Quick Ratio
7.68
Forward P/E
-1.72
Price / Sales
—
Enterprise Value
$-12.65 M
EV / EBITDA
—
EV / Revenue
—
Rating
None
Target Price
—
EPS Forecast (FY)
—
Pros
- Healthy return on equity.
- Short-term liquidity looks comfortable.
- Valuation is not stretched on P/E basis.
Cons
- Capital efficiency is modest.
- Operating margin is thin.
- Net margin is relatively low.
Sift Stocks
| S.No. | Name | Price | P.E. | Market Cap | Div Yld % | ROCE | ROE | 52Week High/ Low | Book Value |
|---|---|---|---|---|---|---|---|---|---|
| 1. | BioRestorative Therapies, Inc. | $0.26 | — | $6.72 M | — | -4386.1% | -3.2% | $2.04 / $0.19 | $0.04 |
| 2. | Taysha Gene Therapies, Inc. | $6.46 | — | $1.85 B | — | -34.88% | -68.45% | $6.5 / $1.13 | $0.87 |
| 3. | Cytokinetics, Incorporated | $65.05 | — | $8.11 B | — | -50.1% | 197.47% | $70.98 / $29.31 | $-5.37 |
| 4. | Cybin D/B/A Helus Pharma | $5.61 | — | $1.92 M | — | -60.35% | -55.89% | $12.7 / $5.9 | $5.49 |
| 5. | Pelthos Therapeutics Inc. | $22.95 | — | $77.23 M | — | -31.06% | -2.4% | $54.29 / $9 | $12.02 |
| 6. | Actuate Therapeutics, Inc. Common stock | $2.62 | — | $54.77 M | — | -270.08% | -5.54% | $11.99 / $1.58 | $0.34 |
| 7. | Keros Therapeutics, Inc. | $11.66 | 2.64 | $230.1 M | — | 21.27% | 19.9% | $22.55 / $10.41 | $15.51 |
Quarterly Results
Figures shown in M / B
| Q1 2026 | Q4 2025 | Q3 2025 | Q2 2025 | Q1 2025 | Q4 2024 | Q3 2024 | |
|---|---|---|---|---|---|---|---|
| Sales | 0 M | 0 M | 0 M | 0 M | 0 M | — | — |
| Operating Profit | -2.12 M | -1.38 M | -0.85 M | -1.04 M | -0.96 M | — | — |
| Net Profit | 0.75 M | -7.42 M | -8.36 M | 11.75 M | -3.05 M | — | — |
| EPS in Rs | 0.07 | -0.69 | -0.78 | 1.09 | -0.28 | -0.39 | — |
Profit & Loss
Figures shown in M / B
| 2025 | 2024 | 2023 | 2022 | |
|---|---|---|---|---|
| Sales | 0 M | 0 M | 0 M | 0 M |
| Operating Profit | -4.38 M | -6.52 M | -6.46 M | -4.39 M |
| Net Profit | 30.66 M | 0.33 M | -4.32 M | -4.24 M |
| EPS in Rs | 2.86 | 0.03 | -0.4 | -0.39 |
Balance Sheet
Figures shown in M / B
| 2025 | 2024 | 2023 | 2022 | |
|---|---|---|---|---|
| Total Assets | 55.17 M | 59.9 M | 73.28 M | 90.62 M |
| Total Liabilities | 3.28 M | 20.39 M | 0.59 M | 0.7 M |
| Equity | 51.89 M | 39.51 M | 72.69 M | 89.92 M |
| Current Assets | 22.38 M | 50.44 M | 68.15 M | 85.49 M |
| Current Liabilities | 2.91 M | 7.42 M | 0.59 M | 0.7 M |
Cash Flow
Last available yearly cash flow history
| 2025 | 2024 | 2023 | 2022 | |
|---|---|---|---|---|
| Operating CF | -2.98 M | -2.15 M | -3.79 M | -4.12 M |
| Investing CF | -7 M | -5 M | 0 M | 0 M |
| Financing CF | -25.03 M | -10.71 M | -13.56 M | 87.31 M |
| Free CF | -2.98 M | -2.15 M | -3.79 M | -4.12 M |
| Capex | — | — | — | — |
5Y Margin & Growth History
Last 5 year derived history from yfinance annual statements
| 2024 | 2023 | 2022 | 2021 | |
|---|---|---|---|---|
| Revenue Growth % | — | — | — | — |
| Earnings Growth % | 107.73% | -1.81% | — | — |
| Profit Margin % | — | — | — | — |
| Operating Margin % | — | — | — | — |
| Gross Margin % | — | — | — | — |
| EBITDA Margin % | — | — | — | — |
Dividend & Split History
Latest dividend and stock split events stored from yfinance
Dividend History
No dividend history available.
Stock Splits
| Date | Split |
|---|---|
| 2021-07-12 | 1:0.000645161 |